Boehringer Ingelheim Circovirus Vaccine Receives Four-Month Duration of Immunity Approval

For Immediate Release

For More Information, Contact:
R. Kelly Schwalbe at 816-474-3166      
             
ST. JOSEPH, Mo. (May 2, 2007) – Boehringer Ingelheim Vetmedica, Inc., (BIVI) announces that the U.S. Animal and Plant Health Inspection Service has approved a duration of immunity (DOI) claim for Ingelvac® CircoFLEX™ of at least four months for porcine circovirus type 2 (PCV2), the primary pathogen for porcine circovirus associated disease (PCVAD).

According to Klaas Okkinga, marketing manager for Boehringer Ingelheim, the approved DOI label extension substantiates extensive research findings that Ingelvac CircoFLEX provides long-lasting protection from PCV2. “A vaccine that provides at least four months of PCV2 immunity is a significant benefit to producers in protecting pigs, both early and late, from damage caused by this disease,” says Okkinga. 

“Currently, Ingelvac CircoFLEX is the only PCV2 vaccine available with proven DOI of this length when administered as a single-dose to pigs 3 weeks of age or older,” Okkinga adds. “Even when administered early, it still protects through the critical period in grow-finish, resulting in reduced pig mortality and improved performance.”

For more information on Ingelvac CircoFLEX vaccine for PCV2, as well as the diagnosis and management of PCVAD, contact Boehringer Ingelheim Vetmedica, Inc., at 800-325-9167.

Boehringer Ingelheim Vetmedica, Inc. (St. Joseph, MO), is a subsidiary of Boehringer Ingelheim Corporation based in Ridgefield, CT and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 137 affiliates in 47 countries and approximately 38,400 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2006, Boehringer Ingelheim posted net sales of US $13.3 billion (10.6 billion euro) while spending approximately one-fifth of net sales in its largest business segment, Prescription Medicines, on research and development.

For more information, please visit:  www.bi-vetmedica.com.